PMID- 30125365
OWN - NLM
STAT- MEDLINE
DCOM- 20181108
LR  - 20210109
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 41
IP  - 9
DP  - 2018 Sep
TI  - The emerging role of novel antihyperglycemic agents in the treatment of heart 
      failure and diabetes: A focus on cardiorenal outcomes.
PG  - 1259-1267
LID - 10.1002/clc.23054 [doi]
AB  - Heart failure (HF) and type 2 diabetes mellitus (T2DM) are two global pandemics, 
      affecting over 25 and 420 million people, respectively. The prevalence of 
      comorbid HF and T2DM is rising, and the prognosis remains poor. One central area 
      of overlap of these two disease processes is renal dysfunction, which contributes 
      to poor cardiovascular outcomes and mortality. As such, there is a growing need 
      for antihyperglycemic agents with cardio- and renoprotective effects. Three 
      classes of novel antihyperglycemic agents, sodium-glucose cotransporter-2 (SGLT2) 
      inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl 
      peptidase-4 (DPP4) inhibitors have demonstrated varied cardiorenal outcomes in 
      recent cardiovascular outcomes trials. Understanding the differential effects of 
      these agents, together with their proposed mechanisms, is crucial for the 
      development of safe and effective treatment regimens and future pharmacologic 
      targets for HF and T2DM. In this review, we discuss the overlapping 
      pathophysiology of HF and T2DM, summarize outcomes data for the novel 
      antihyperglycemic agents and proposed mechanisms of action, and review how the 
      current evidence informs future management of comorbid HF and T2DM.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - McHugh, Kelly R
AU  - McHugh KR
AUID- ORCID: 0000-0001-8994-5577
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
FAU - DeVore, Adam D
AU  - DeVore AD
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
FAU - Mentz, Robert J
AU  - Mentz RJ
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
FAU - Edmonston, Daniel
AU  - Edmonston D
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
FAU - Green, Jennifer B
AU  - Green JB
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
FAU - Hernandez, Adrian F
AU  - Hernandez AF
AUID- ORCID: 0000-0003-3387-9616
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina.
AD  - Duke Clinical Research Institute, Duke University School of Medicine, Durham, 
      North Carolina.
LA  - eng
GR  - Novartis/
GR  - Merck/
GR  - Luitpold/
GR  - GlaxoSmithKline/
GR  - AstraZeneca/
GR  - Intarcia Therapeutics, Inc/
GR  - ResMed/
GR  - Otsuka/
GR  - Medtronic/
GR  - Gilead/
GR  - Bayer/
GR  - Amgen/
GR  - NHLBI/
GR  - American Heart Association/
GR  - Duke Clinical Research Institute, Durham, NC/
GR  - U01 HL125511/HL/NHLBI NIH HHS/United States
GR  - U10HL110312/NH/NIH HHS/United States
GR  - R01AG045551-01A1/NH/NIH HHS/United States
GR  - U10 HL110312/HL/NHLBI NIH HHS/United States
GR  - U01HL125511-01A1/NH/NIH HHS/United States
GR  - R01 AG045551/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20180921
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Triglycerides)
RN  - Hypertryptophanemia, Familial
SB  - IM
MH  - Amino Acid Metabolism, Inborn Errors/blood/*drug therapy/epidemiology
MH  - *Cardio-Renal Syndrome/blood/epidemiology/prevention & control
MH  - Comorbidity/trends
MH  - Diabetes Mellitus, Type 2/blood/*epidemiology
MH  - Global Health
MH  - *Heart Failure/blood/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Triglycerides/*blood
PMC - PMC6490104
OTO - NOTNLM
OT  - diabetes
OT  - heart failure
OT  - kidney disease
EDAT- 2018/08/21 06:00
MHDA- 2018/11/09 06:00
PMCR- 2018/09/21
CRDT- 2018/08/21 06:00
PHST- 2018/05/29 00:00 [received]
PHST- 2018/08/10 00:00 [revised]
PHST- 2018/08/15 00:00 [accepted]
PHST- 2018/08/21 06:00 [pubmed]
PHST- 2018/11/09 06:00 [medline]
PHST- 2018/08/21 06:00 [entrez]
PHST- 2018/09/21 00:00 [pmc-release]
AID - CLC23054 [pii]
AID - 10.1002/clc.23054 [doi]
PST - ppublish
SO  - Clin Cardiol. 2018 Sep;41(9):1259-1267. doi: 10.1002/clc.23054. Epub 2018 Sep 21.